ProMetic Life Sciences, Inc.’s UK subsidiary, ProMetic Biosciences, Ltd. (PBL), has entered into an agreement with Novartis Vaccines and Diagnostics to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine. Under the terms of the agreement PBL will receive funding from Novartis to screen its Chemical Combinatorial Libraries for ligands suitable for the process scale purification of a new vaccine product by Novartis currently undergoing clinical...